Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain And Hypoglycemia Risk For Diabetes Patients

The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA® (insulin human [rDNA origin]) Inhalation Powder combined with basal insulin is comparable to standard of care therapies in controlling post-meal blood sugar levels, and also results in significantly less weight gain and risk of hypoglycemia for adult patients with diabetes. The data were presented at the American Diabetes Association’s 69th Scientific Sessions.

More: continued here

Filed under: Diabetes on June 10th, 2009